Crescita Therpeutc (TSE:CTX) has released an update.
Crescita Therapeutics Inc. experienced a challenging fiscal year in 2023, with a significant 26% drop in annual revenue largely due to decreased production for a major client. Despite this downturn, the skincare segment of the business grew by 30%, surpassing the beauty industry’s growth projections. The company remains optimistic about future prospects, including potential licensing deals and a strong cash position to fund strategic investments.
For further insights into TSE:CTX stock, check out TipRanks’ Stock Analysis page.
